SCHEMBL13934797

SCHEMBL13934797

O=C(O[C@@H]1Cc2c(O)cc(O)c([C@H]3c4c(O)cc(O)cc4O[C@H](c4ccc(O)c(O)c4)[C@@H]3O)c2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKD3 O94806 4/20 0.84
▸ PRKCG P05129 4/20 0.84
▸ PRKCB P05771 4/20 0.84
▸ PRKCA P17252 4/20 0.84
▸ PRKCH P24723 4/20 0.84
▸ PRKCI P41743 4/20 0.84
▸ PRKCE Q02156 4/20 0.84
▸ PRKCQ Q04759 4/20 0.84
▸ PRKCZ Q05513 4/20 0.84
▸ PRKCD Q05655 4/20 0.84
▸ PRKD1 Q15139 4/20 0.84
▸ PTGS2 P35354 1/20 0.75
▸ SNCA P37840 5/20 0.70
▸ DYRK1A Q13627 4/20 0.70
▸ BCL2 P10415 3/20 0.70
▸ PSMB5 P28074 3/20 0.70
▸ PGD P52209 3/20 0.70
▸ ALOX15 P16050 3/20 0.70
▸ HSD17B10 Q99714 3/20 0.70
▸ PKM P14618 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25182577 1.00 PRKD3 (0.84) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL13934793 1.00 PRKD3 (0.84) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL22295330 0.99 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL30834797 0.99 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL30538719 0.99 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL29437883 0.99 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL30834898 0.99 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL22821108 0.98 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL22295316 0.98 PRKD3 (0.85) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL13934799 0.95 PTGS2 (0.82) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151329-A1 METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER NAGASAKI UNIVERSITY (JP) 2016-06-02 — — US disclosed
US-20160151329-A1 METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER NAGASAKI UNIVERSITY (JP) 2016-06-02 — — US disclosed
US-20090047305-A1 METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER NAGASAKI UNIVERSITY (JP) 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151329-A1 METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER MLN, NOD2, WDR48 PRKD3 2726/4885PRKCG 926/4885PRKCB 1716/4885
US-20090047305-A1 METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER MLN, NOD2, PRRC2C PRKD3 2335/4885PRKCG 705/4885PRKCB 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback